# South Korea Formulation Development Outsourcing Market

> South Korea Formulation Development Outsourcing Market Research Report By Services (Pre Formulation Services, Formulation Optimization), By Dosage Form (Injectable, Oral, Topical, Inhaled, Others), By Application (Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, Others) and By End User (Pharmaceutical and Biopharmaceutical, Government, Academic Institutes) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.09%
- **2024:** $ 219.67 Million
- **2025:** $ 237.44 Million
- **2035:** $ 517 Million
- **Key Players:** Boehringer Ingelheim (DE), Lonza Group (CH), Catalent (US), Evonik Industries (DE), Fujifilm Diosynth Biotechnologies (JP), Samsung Biologics (KR), WuXi AppTec (CN), Charles River Laboratories (US), Piramal Pharma Solutions (IN)

**Report ID:** MRFR/Pharma/48421-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-formulation-development-outsourcing-market-50178

---

## Market Summary

## **South Korea Formulation Development Outsourcing Market Overview**

As per MRFR analysis, the South Korea Formulation Development Outsourcing Market Size was estimated at 230.99 (USD Million) in 2023. The South Korea Formulation Development Outsourcing Market Industry is expected to grow from 250(USD Million) in 2024 to 710 (USD Million) by 2035. The South Korea Formulation Development Outsourcing Market CAGR (growth rate) is expected to be around 9.954% during the forecast period (2025 - 2035)

**Key South Korea Formulation Development Outsourcing Market Trends Highlighted**

The South Korea formulation development outsourcing market is witnessing significant growth driven by various key market drivers. The increasing demand for innovative pharmaceutical products has prompted local companies to seek out external expertise in formulation development. South Korea's robust biotechnology sector, backed by government initiatives and funding, further spurs the trend of outsourcing, allowing pharmaceutical firms to focus on core activities while leveraging specialized knowledge from service providers. 

The local industry benefits from a highly skilled workforce and advanced research facilities, making South Korea an attractive location for formulation development.In recent times, there has been a noticeable shift towards green chemistry and sustainable practices within the formulation development process. As South Korea positions itself as a leader in eco-friendly technologies, companies are increasingly looking for service providers that adhere to sustainable practices. The rise of personalized medicine has opened up additional opportunities for formulation development, where outsourcing can be an effective strategy to manage complex requirements and enhance the production of tailor-made therapies. 

Moreover, the growth of contract research organizations (CROs) in South Korea is creating new opportunities for pharmaceutical companies to access a broader range of services and expertise.This trend aligns with the overall globalization of the pharmaceutical industry, where South Korean firms are looking to establish partnerships and collaborations beyond local boundaries. 

Embracing digital transformation with advanced technologies like artificial intelligence and analytics is also emerging, providing companies with innovative solutions to improve their formulation strategies while streamlining processes. These dynamics are set to shape the future of formulation development outsourcing in South Korea, ensuring the market remains competitive and innovative.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Formulation Development Outsourcing Market Drivers**

**Rising Investment in Biopharmaceutical Research and Development**

The growing investment in biopharmaceutical research and development (R&D) is a major driver of the South Korea formulation development outsourcing market. With more than 1.2 billion USD set aside to assist different R&D activities in the biopharmaceutical industry, the South Korean government has made significant financing available for these efforts. Enhancing drug development skills and promoting innovation in pharmaceutical formulations are the goals of this initiative. 

Leading companies like SK Biopharmaceuticals and Samsung Biologics are spearheading this effort, demonstrating how public-private collaborations may significantly improve the formulation development environment. Given that South Korea wants to rank among the top regional leaders in this sector, the government's assistance is in line with its plans to promote a competitive biopharmaceutical industry. Over the next ten years, the South Korea Formulation Development Outsourcing Market is anticipated to increase because of these significant expenditures.

**Increasing Demand for Personalized Medicine**

The demand for personalized medicine is rapidly growing, influencing the South Korea Formulation Development Outsourcing Market Industry. As patients increasingly seek customized treatments based on genetic profiling, pharmaceutical companies must adapt their formulation approaches to cater to these specific needs. In South Korea, the Ministry of Health and Welfare has launched initiatives to promote personalized healthcare, reflecting a significant shift towards individualized treatment options.

Companies like Celltrion are actively developing tailored formulations while leveraging advanced technologies. This trend is expected to increase outsourcing as firms look for specialized expertise in formulation development, thereby driving market growth.

**Advancements in Drug Delivery Technologies**

Technological advancements in drug delivery systems are serving as a crucial driver for the South Korea Formulation Development Outsourcing Market Industry. Innovations in nanoparticle technology and targeted delivery mechanisms are reshaping how drugs are formulated and administered. South Korea's commitment to advancing biotech innovation, evidenced by the establishment of the Korea Bio Association, supports research in cutting-edge drug delivery technologies.Companies like Hanmi Pharmaceutical are at the forefront, focusing on innovative formulation techniques to improve therapeutic efficacy. As these technologies become more prevalent, the need for specialized formulation development services is anticipated to rise, catalyzing market expansion.

**South Korea Formulation Development Outsourcing Market Segment Insights**

**Formulation Development Outsourcing Market Services Insights**

The Services segment of the South Korea Formulation Development Outsourcing Market is witnessing remarkable growth, driven by the increasing demand for efficient and cost-effective product development solutions within the pharmaceutical and biotechnology sectors. The region has become a hub for innovative research and development, with South Korea's government actively promoting initiatives aimed at boosting its pharmaceutical capabilities. Among the various services, Pre Formulation Services play a critical role by laying the groundwork for successful formulation development. 

This phase involves the assessment of active pharmaceutical ingredients (APIs) physical and chemical properties, which is essential to tailor suitable formulation strategies. The significance of Pre Formulation Services lies in their ability to identify potential challenges early in the development process, thereby reducing the risks of failure during later stages. In addition, Formulation Optimization is gaining traction as manufacturers strive to enhance product performance, stability, and bioavailability. This service focuses on refining existing formulations by employing advanced analytical techniques and innovative methodologies, which are increasingly important in today’s competitive landscape.

The need for improved drug delivery systems and patient-centric formulations is propelling the demand for formulation optimization services. 

Companies are recognizing the value these services provide in enabling faster time-to-market and increased profitability. Moreover, as the South Korean pharmaceutical industry is experiencing rapid growth due to the rise of chronic diseases and an aging population, there is a surge in the requirement for specialized formulation development solutions. The market dynamics underscore the opportunity for service providers to capitalize on the growing trends in personalized medicine and biologics, further driving the expansion of the South Korea Formulation Development Outsourcing Market. 

Overall, the Services segment represents not just a vital component within the market but also indicates the industry's shift towards more refined and strategic approaches to formulation development amidst a challenging healthcare environment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Formulation Development Outsourcing Market Dosage Form Insights**

The South Korea Formulation Development Outsourcing Market has shown notable expansion within the Dosage Form segment, which encompasses various forms such as Injectable, Oral, Topical, Inhaled, and Others. Injectable dosage forms are particularly significant due to their effectiveness in administering biologics and other therapies that require precise delivery, thereby driving substantial demand in hospitals and clinics. Oral dosage forms hold a dominant position because of their convenience and patient compliance, which cater to a large segment of the population seeking easy administration.

Topical formulations also play a vital role, especially in dermatology, as they provide localized treatment with fewer systemic effects, appealing to both manufacturers and consumers. Inhaled formulations are gaining traction, particularly for respiratory diseases, benefitting from advancements in aerosol technologies. Other dosage forms expand the market with innovations that address niche patient needs. Overall, the diversification in Dosage Form options reflects the growing need for customized patient care, and this segment represents a dynamic area of growth within the South Korea Formulation Development Outsourcing Market, driven by technological advancements and changing healthcare demands.

**Formulation Development Outsourcing Market Application Insights**

The Application segment of the South Korea Formulation Development Outsourcing Market plays a crucial role in addressing the diverse healthcare requirements of the population. This segment encompasses key areas like Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, and others, reflecting the multifaceted approach needed to tackle various health challenges. Oncology remains significant due to the rising prevalence of cancer, leading to increased demand for targeted therapeutics and innovative formulations. Genetic Disorders also show dominance as advancements in gene therapy continue to foster the need for specialized formulations tailored to individual patient requirements.

Neurology's importance is underscored by the growing incidence of neurodegenerative diseases, which require extensive formulation research to develop effective treatments. Infectious Disease formulations are critical, especially in the context of evolving pathogens and the need for robust vaccine development, while the Respiratory segment's prominence arises from the increasing asthma and chronic obstructive pulmonary disease cases in South Korea.

The Cardiovascular segment is significant due to the rising rates of heart disease among the aging population, driving innovation in formulation development.Other emerging applications highlight the ongoing trends toward personalized medicine and the increasing complexity of drug development, further enhancing the role of the Formulation Development Outsourcing Market in South Korea’s healthcare landscape.

**Formulation Development Outsourcing Market End User Insights**

The End User segment of the South Korea Formulation Development Outsourcing Market is pivotal in driving growth and innovation within the industry. This segment can be primarily characterized by three main categories: Pharmaceutical and Biopharmaceutical companies, Government entities, and Academic Institutes. The Pharmaceutical and Biopharmaceutical category largely dominates the market, reflecting the significant demand for novel drug formulations and therapies, underscored by Research and Development initiatives aimed at advancing healthcare outcomes.

Furthermore, Government involvement in the market fosters regulatory compliance and promotes policies that enhance research capabilities, making it essential in shaping the landscape of formulation development. Academic Institutes play a crucial role by fostering collaboration with industry players, helping to bridge the gap between theoretical research and practical application.

With South Korea's robust healthcare system and commitment to innovation, these End Users collectively contribute to a vibrant ecosystem that supports the evolution of formulation development outsourcing.The growing focus on tailored drug solutions and personalized medicine continues to pave the way for strategic partnerships between these entities, enhancing the overall efficiency and effectiveness of drug development processes.

**South Korea Formulation Development Outsourcing Market Key Players and Competitive Insights**

The South Korea Formulation Development Outsourcing Market has gained significant momentum due to its expanding biopharmaceutical sector, which is driven by increasing demand for innovative drug solutions and efficient manufacturing processes. Companies operating in this market are positioned to leverage advanced technologies and collaborative ventures, ensuring a competitive edge in formulation development services. The outsourcing landscape is marked by a strong presence of both local and international players, each aiming to capture the growing opportunities presented by advancements in research and development.

As biopharma companies increasingly focus on streamlining operations and reducing time-to-market, outsourcing formulation development has become a pivotal strategy for optimizing resources and achieving operational flexibility.

Medytox stands out as a key player in the South Korea Formulation Development Outsourcing Market, particularly known for its specialized expertise in biopharmaceutical formulation and development services. The company possesses a robust portfolio that emphasizes the creation of innovative therapeutic solutions which cater to the specific needs of the local and regional markets. Medytox's strength lies in its strong R&D capabilities and its commitment to delivering high-quality formulation development services that align with the stringent regulatory standards within South Korea.

This focus on quality and innovation positions Medytox as a trusted partner for biopharmaceutical companies seeking to efficiently navigate the complexities of drug development and commercialization.

SK Biopharmaceuticals has established a commendable presence in the South Korea Formulation Development Outsourcing Market, recognized for its comprehensive range of products and services tailored to the biopharmaceutical industry. The company specializes in both the development and manufacturing of advanced drug formulations, providing end-to-end solutions that optimize efficiency and effectiveness for clients. SK Biopharmaceuticals capitalizes on its extensive expertise and resources to develop cutting-edge therapies, particularly in the realm of neurological disorders. 

The company has been active in fostering innovation through strategic mergers and acquisitions, enhancing its capabilities and market reach. This proactive approach not only strengthens SK Biopharmaceuticals' service offerings but also supports its position as a preferred partner for organizations in the highly competitive biopharmaceutical landscape in South Korea.

**Key Companies in the South Korea Formulation Development Outsourcing Market Include**

**South Korea Formulation Development Outsourcing Market Industry Developments**

The South Korea Formulation Development Outsourcing Market has seen significant developments recently, particularly with major players engaged in various activities. In October 2023, Medytox announced a partnership with AptarGroup to enhance innovative drug delivery systems, reflecting an upward trend in collaborative efforts. SK Biopharmaceuticals has also gained traction with its expanding pipeline, contributing to a forecasted market growth that is optimistic. Major firms like Pfizer and Roche continue to seek partnerships to fortify their local presence, demonstrating the strategic significance of the region. 

In terms of mergers and acquisitions, Celltrion completed its acquisition of a minority stake in Genexine back in June 2023, which has strengthened both companies' positions in the biosimilar market. This acquisition reflects a broader trend of consolidation within the sector as firms aim to enhance capacity and capabilities. The Korea Pharmaceutical and BioPharma Manufacturers Association noted that investments in biotechnology and formulation development are driving further advancements, underscoring the growth potential in the country.

Recent governmental support in research initiatives has also led to an increase in funding for formulation development, echoing South Korea's commitment to being a hub for pharmaceutical innovation.

**South Korea Formulation Development Outsourcing Market Segmentation Insights**

## Market Drivers

### Increasing Investment in R&D

The formulation development-outsourcing market in South Korea is experiencing a surge in investment in research and development (R&D). This trend is driven by the need for innovative drug formulations and the growing complexity of therapeutic agents. In 2025, R&D spending in the pharmaceutical sector is projected to reach approximately $3 billion, reflecting a 15% increase from previous years. Companies are increasingly outsourcing formulation development to specialized firms to leverage their expertise and reduce time-to-market. This strategy allows pharmaceutical companies to focus on core competencies while ensuring high-quality formulations. The competitive landscape is evolving, with a notable rise in partnerships between local firms and international players, enhancing the capabilities within the formulation development-outsourcing market. As a result, the market is likely to expand, driven by the demand for novel therapies and the need for efficient development processes.

### Regulatory Landscape Adaptation

The regulatory landscape in South Korea is evolving, which presents both challenges and opportunities for the formulation development-outsourcing market. As regulatory bodies implement stricter guidelines for drug development, companies are increasingly seeking outsourcing partners with expertise in compliance and quality assurance. This trend is particularly relevant in the context of biologics and complex formulations, where adherence to regulations is critical. In 2025, the market for regulatory consulting services is expected to grow by 18%, reflecting the increasing importance of regulatory compliance in formulation development. Outsourcing formulation development allows companies to leverage the knowledge of specialized firms that are well-versed in navigating the regulatory environment. As a result, the formulation development-outsourcing market is likely to expand, driven by the need for efficient and compliant development processes.

### Expansion of Biopharmaceutical Sector

The biopharmaceutical sector in South Korea is expanding rapidly, which is positively impacting the formulation development-outsourcing market. With the increasing number of biopharmaceutical companies entering the market, there is a heightened demand for specialized formulation services. In 2025, the biopharmaceutical market is projected to reach $10 billion, growing at a rate of 12% annually. This growth is attributed to the rising prevalence of diseases and the need for innovative therapies. Outsourcing formulation development allows biopharmaceutical companies to efficiently navigate the complexities of biologics, ensuring compliance with stringent regulatory standards. As the sector continues to evolve, the formulation development-outsourcing market is likely to see increased collaboration between biopharmaceutical firms and outsourcing partners, fostering innovation and enhancing the overall quality of drug formulations.

### Growing Demand for Personalized Medicine

The formulation development-outsourcing market is witnessing a growing demand for personalized medicine in South Korea. As healthcare shifts towards tailored therapies, the need for customized formulations is becoming increasingly apparent. This trend is supported by advancements in genomics and biotechnology, which enable the development of targeted therapies. In 2025, the market for personalized medicine is expected to grow by 20%, indicating a significant shift in treatment paradigms. Outsourcing formulation development allows companies to access specialized knowledge and technologies required for creating these bespoke solutions. Furthermore, the increasing prevalence of chronic diseases necessitates innovative approaches to treatment, further driving the demand for personalized formulations. Consequently, the formulation development-outsourcing market is likely to benefit from this trend, as companies seek to meet the unique needs of patients through customized therapeutic options.

### Technological Integration in Formulation Processes

Technological integration is transforming the formulation development-outsourcing market in South Korea. The adoption of advanced technologies, such as artificial intelligence and machine learning, is streamlining formulation processes and enhancing efficiency. In 2025, it is anticipated that 30% of formulation development activities will incorporate these technologies, leading to faster and more accurate outcomes. Companies are increasingly outsourcing to firms that utilize cutting-edge technologies, allowing them to remain competitive in a rapidly evolving market. This trend not only improves the quality of formulations but also reduces costs associated with development. As technological advancements continue to shape the industry, the formulation development-outsourcing market is likely to experience significant growth, driven by the demand for innovative and efficient formulation solutions.

## Future Outlook

The [Formulation Development Outsourcing Market](https://www.marketresearchfuture.com/reports/formulation-development-outsourcing-market-10387) is projected to grow at an 8.09% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for customized solutions.

**New opportunities:**

- Investment in AI-driven formulation optimization tools.
- Expansion of contract manufacturing partnerships for niche products.
- Development of sustainable packaging solutions for formulations.

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovation.

## Segment Insights

### By Services: Pre Formulation Services (Largest) vs. Formulation Optimization (Fastest-Growing)

In the South Korea formulation development-outsourcing market, Pre Formulation Services hold a significant market share, showcasing their dominance due to their critical role in the early stages of product development. These services encompass essential analysis and testing, ensuring formulations are robust from the outset. Meanwhile, Formulation Optimization is rapidly gaining traction, driven by the need for cost-effective and efficient formulation processes that meet client specifications and regulatory requirements.

Growth trends in the South Korea formulation development-outsourcing market indicate a rising demand for both services, but Formulation Optimization stands out as the fastest-growing segment. Companies are increasingly investing in advanced technologies and methodologies to improve formulation precision and reduce time-to-market. This shift is propelled by a competitive landscape that requires greater efficiency and innovation, fostering a favorable environment for these emerging services.

Pre Formulation Services (Dominant) vs. Formulation Optimization (Emerging)

Pre Formulation Services are predominant in the South Korea formulation development-outsourcing market due to their foundational importance in establishing quality formulations that comply with therapeutic standards. These services are characterized by rigorous testing and analysis which form the backbone of product efficacy. In contrast, Formulation Optimization, though emerging, is rapidly evolving as a vital component, focusing on refining existing formulas for better performance and reduced costs. The demand for quicker turnarounds and improved formulations is driving innovation in this area, positioning it strategically for future growth. This juxtaposition highlights how both segments cater to different yet crucial aspects of formulation development.

### By Dosage Form: Injectable (Largest) vs. Oral (Fastest-Growing)

In the South Korea formulation development-outsourcing market, the dosage form segment is significantly dominated by injectables, accounting for a substantial share. This prevalence is attributed to the rising demand for biologics and complex therapeutics that require a parenteral route of administration. On the other hand, oral dosage forms have been emerging strongly, marked by advancements in drug formulation technologies that enhance bioavailability and patient compliance.

Growth trends indicate a shift towards personalized medicine and innovative therapeutic solutions, driving the development of both injectable and oral forms. The injectable segment is supported by a robust pipeline of biologic drugs, while the oral segment benefits from extensive research aimed at improving drug delivery systems. Advances in manufacturing processes and regulatory support further contribute to the rapid expansion of the oral dosage form category.

Injectable (Dominant) vs. Oral (Emerging)

The injectable dosage form remains dominant in the South Korea formulation development-outsourcing market, largely due to its critical role in delivering biologics and vaccines. This form is preferred for conditions requiring immediate effects and precise dosing strategies. In contrast, the oral dosage form is emerging rapidly as an attractive alternative, driven by innovations that facilitate patient-friendly administration and improve absorption profiles. These innovations include the development of novel excipients and drug formulations that cater to patient preferences, minimizing the risks associated with injectable therapies. The dual focus on safety and efficacy in drug development is reshaping competition in the market, fostering partnerships between formulators and healthcare providers.

### By Application: Oncology (Largest) vs. Neurology (Fastest-Growing)

In the South Korea formulation development-outsourcing market, the application segment is primarily dominated by oncology, which captures the largest share due to the rising prevalence of cancer and increasing investments in oncology research. Following oncology, other applications such as infectious disease and neurology are gaining traction, but to a lesser extent. Genetic disorders and respiratory diseases also contribute to the sector, albeit with smaller shares compared to the leading segments.

Recent trends indicate that neurology is emerging as the fastest-growing application area within the South Korea formulation development-outsourcing market. The drive towards innovative treatment solutions for neurodegenerative diseases and mental health conditions is propelling growth in this sector. Moreover, collaborations between pharmaceutical companies and biotech firms are expected to further enhance development capabilities, accelerating the pace of advancements in neurology therapy formulations.

Oncology: Dominant vs. Neurology: Emerging

Oncology remains the dominant application segment in the South Korea formulation development-outsourcing market, underpinned by a surge in cancer cases and a strong focus on oncology drug formulations. The sector benefits from robust R&D investments and strategic partnerships aimed at developing novel therapies and personalized medicine solutions. On the other hand, neurology is an emerging segment driven by a growing understanding of neurological disorders and the need for innovative treatments, particularly for conditions like Alzheimer's and Parkinson's disease. This segment is characterized by fast-paced research initiatives and increasing interest from both established pharmaceutical firms and emerging biotech companies, setting the stage for significant advancements in formulation development.

### By End User: Pharmaceutical and Biopharmaceutical (Largest) vs. Government (Fastest-Growing)

In the South Korea formulation development-outsourcing market, the distribution of market share reveals that the Pharmaceutical and Biopharmaceutical sector holds a commanding position. This segment capitalizes on the robust demand for innovation in drug development and the growing prevalence of chronic diseases, which necessitate advanced formulations. Government institutions, while relatively smaller in market share compared to the dominant pharmaceutical players, are rapidly increasing their presence, driven by substantial investments in healthcare research and regulatory initiatives.

As the healthcare landscape evolves, growth trends within these sectors indicate a shift towards outsourcing formulation development to improve efficiency and focus on core competencies. The Pharmaceutical and Biopharmaceutical segments are witnessing a surge in partnerships with contract development organizations to expedite drug discovery. Simultaneously, Government support for biopharmaceutical initiatives is fostering innovation, leading to increased outsourcing opportunities and driving the sector's growth in the coming years.

Pharmaceutical and Biopharmaceutical (Dominant) vs. Academic Institutes (Emerging)

The Pharmaceutical and Biopharmaceutical segment stands out as the dominant force in the South Korea formulation development-outsourcing market, characterized by extensive investments in research and development alongside a strong regulatory framework. This sector prioritizes cutting-edge technologies and innovative approaches to formulation development, seeking to enhance drug efficacy and safety. In contrast, Academic Institutes represent an emerging segment, focusing on foundational research and collaboration with industry players. While their influence is less pronounced, they play a crucial role in driving scientific advancements and contribute significantly to the innovation pipeline. As these institutions partner with pharmaceutical companies for research projects, their position in the market is gradually strengthening, making them a vital part of the overall ecosystem.

## Competitive Benchmarking

The formulation development-outsourcing market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for biopharmaceuticals and a growing emphasis on innovation. Key players such as Boehringer Ingelheim (DE), Lonza Group (CH), and Samsung Biologics (KR) are strategically positioned to leverage their extensive capabilities in bioprocessing and formulation development. These companies focus on enhancing operational efficiencies through technological advancements and strategic partnerships, which collectively shape a competitive environment that is increasingly reliant on innovation and agility.
In terms of business tactics, companies are localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. However, the influence of major companies like Fujifilm Diosynth Biotechnologies (JP) and WuXi AppTec (CN) is notable, as they continue to expand their service offerings and geographic reach, thereby intensifying competition.
In October 2025, Lonza Group (CH) announced a significant investment in its South Korean facilities, aimed at expanding its capabilities in cell and gene therapy development. This strategic move is likely to enhance Lonza's position in the rapidly growing biopharmaceutical sector, allowing it to cater to the increasing demand for advanced therapies. The investment underscores Lonza's commitment to innovation and its intent to solidify its market presence in South Korea.
In September 2025, Samsung Biologics (KR) revealed plans to establish a new state-of-the-art manufacturing facility in Incheon, which is expected to double its production capacity. This expansion is indicative of Samsung's strategy to meet the surging demand for biologics and to enhance its competitive edge in the formulation development space. By increasing its production capabilities, Samsung Biologics aims to attract more global clients seeking reliable and scalable manufacturing solutions.
In August 2025, Boehringer Ingelheim (DE) entered into a strategic partnership with a local South Korean biotech firm to co-develop innovative drug formulations. This collaboration is expected to leverage both companies' strengths, facilitating faster development timelines and improved market access for new therapies. Such partnerships reflect a growing trend in the market, where collaboration is seen as a key driver of innovation and efficiency.
As of November 2025, the competitive trends in the formulation development-outsourcing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the need to pool resources and expertise to navigate complex market demands. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, positioning companies to better meet the needs of a rapidly changing market.

## Recent News & Developments

The South Korea Formulation Development Outsourcing Market has seen significant developments recently, particularly with major players engaged in various activities. In October 2023, Medytox announced a partnership with AptarGroup to enhance innovative drug delivery systems, reflecting an upward trend in collaborative efforts. SK Biopharmaceuticals has also gained traction with its expanding pipeline, contributing to a forecasted market growth that is optimistic. Major firms like Pfizer and Roche continue to seek partnerships to fortify their local presence, demonstrating the strategic significance of the region. 

In terms of mergers and acquisitions, Celltrion completed its acquisition of a minority stake in Genexine back in June 2023, which has strengthened both companies' positions in the biosimilar market. This acquisition reflects a broader trend of consolidation within the sector as firms aim to enhance capacity and capabilities. The Korea Pharmaceutical and BioPharma Manufacturers Association noted that investments in biotechnology and formulation development are driving further advancements, underscoring the growth potential in the country.

Recent governmental support in research initiatives has also led to an increase in funding for formulation development, echoing South Korea's commitment to being a hub for pharmaceutical innovation.

## Report Scope

| MARKET SIZE 2024 | 219.67(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 237.44(USD Million) |
| MARKET SIZE 2035 | 517.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.09% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Boehringer Ingelheim (DE), Lonza Group (CH), Catalent (US), Evonik Industries (DE), Fujifilm Diosynth Biotechnologies (JP), Samsung Biologics (KR), WuXi AppTec (CN), Charles River Laboratories (US), Piramal Pharma Solutions (IN) |
| Segments Covered | Services, Dosage Form, Application, End User |
| Key Market Opportunities | Growing demand for innovative formulations driven by regulatory changes and consumer preferences in the formulation development-outsourcing market. |
| Key Market Dynamics | Rising demand for innovative formulations drives competitive outsourcing partnerships in South Korea's formulation development sector. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What is the current market valuation of the formulation development-outsourcing market in South Korea?**
A: The market valuation was $219.67 Million in 2024.

**Q: What is the projected market size for the formulation development-outsourcing market by 2035?**
A: The market is projected to reach $517.0 Million by 2035.

**Q: What is the expected CAGR for the formulation development-outsourcing market during the forecast period?**
A: The expected CAGR for the market from 2025 - 2035 is 8.09%.

**Q: Which companies are considered key players in the formulation development-outsourcing market?**
A: Key players include Boehringer Ingelheim, Lonza Group, Catalent, and Samsung Biologics.

**Q: What are the main service segments in the formulation development-outsourcing market?**
A: Main service segments include Pre Formulation Services and Formulation Optimization.

**Q: What is the valuation range for Pre Formulation Services in the market?**
A: The valuation for Pre Formulation Services ranges from $60.0 Million to $140.0 Million.

**Q: What dosage forms are included in the formulation development-outsourcing market?**
A: Dosage forms include Injectable, Oral, Topical, Inhaled, and Others.

**Q: What is the projected valuation for Oral dosage forms by 2035?**
A: The projected valuation for Oral dosage forms is between $80.0 Million and $200.0 Million.

**Q: Which applications are driving growth in the formulation development-outsourcing market?**
A: Applications driving growth include Oncology, Genetic Disorders, and Neurology.

**Q: What is the expected valuation for the Pharmaceutical and Biopharmaceutical end-user segment?**
A: The expected valuation for the Pharmaceutical and Biopharmaceutical segment ranges from $110.0 Million to $250.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-formulation-development-outsourcing-market-50178*